Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 366
7
Diseases
32
Unique genes
0.244
Avg. similarity score
Muscle eye brain disease
Most-connected disease (6 links)
Disease
Searched: Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a
Muscle eye brain disease
Walker-warburg syndrome
Congenital muscular dystrophy
Congenital muscular dystrophy due to dystroglycanopathy
Myopathy caused by variation in CRPPA
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a13
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Muscle eye brain disease | 6 | 6 | 15 |
| Walker-warburg syndrome | 6 | 6 | 16 |
| Congenital muscular dystrophy | 5 | 5 | 23 |
| Congenital muscular dystrophy due to dystroglycanopathy | 4 | 4 | 7 |
| Myopathy caused by variation in CRPPA | 4 | 4 | 1 |
| Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a | 3 | 3 | 6 |
| Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a13 | 2 | 2 | 2 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| CRPPA | 5 / 7 | Congenital muscular dystrophy, Congenital muscular dystrophy due to dystroglycanopathy, Muscle eye brain disease, Myopathy caused by variation in CRPPA and 1 more |
| POMGNT1 | 5 / 7 | Congenital muscular dystrophy, Congenital muscular dystrophy due to dystroglycanopathy, Muscle eye brain disease, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a and 1 more |
| FKRP | 4 / 7 | Congenital muscular dystrophy, Congenital muscular dystrophy due to dystroglycanopathy, Muscle eye brain disease, Walker-warburg syndrome |
| FKTN | 4 / 7 | Congenital muscular dystrophy, Muscle eye brain disease, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, Walker-warburg syndrome |
| GMPPB | 4 / 7 | Congenital muscular dystrophy, Congenital muscular dystrophy due to dystroglycanopathy, Muscle eye brain disease, Walker-warburg syndrome |
| LARGE1 | 4 / 7 | Congenital muscular dystrophy, Congenital muscular dystrophy due to dystroglycanopathy, Muscle eye brain disease, Walker-warburg syndrome |
| POMK | 4 / 7 | Congenital muscular dystrophy, Muscle eye brain disease, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, Walker-warburg syndrome |
| POMT1 | 4 / 7 | Congenital muscular dystrophy, Muscle eye brain disease, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, Walker-warburg syndrome |
| POMT2 | 4 / 7 | Congenital muscular dystrophy, Muscle eye brain disease, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, Walker-warburg syndrome |
| B3GALNT2 | 3 / 7 | Congenital muscular dystrophy due to dystroglycanopathy, Muscle eye brain disease, Walker-warburg syndrome |
| B4GAT1 | 3 / 7 | Muscle eye brain disease, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a13, Walker-warburg syndrome |
| DAG1 | 3 / 7 | Muscle eye brain disease, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, Walker-warburg syndrome |
| POMGNT2 | 2 / 7 | Muscle eye brain disease, Walker-warburg syndrome |
| RXYLT1 | 2 / 7 | Muscle eye brain disease, Walker-warburg syndrome |
| TSPAN1 | 2 / 7 | Congenital muscular dystrophy due to dystroglycanopathy, Muscle eye brain disease |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Mannose type O-glycan biosynthesis | KEGG | 12 / 23 | 196× | 1.61e-26 | 3.09e-23 ✓ sig. |
| O-linked glycosylation | Reactome | 9 / 10 | 338× | 1.96e-23 | 2.29e-20 ✓ sig. |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | Reactome | 3 / 3 | 375× | 1.72e-8 | 1.14e-6 ✓ sig. |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | Reactome | 3 / 3 | 375× | 1.72e-8 | 1.14e-6 ✓ sig. |
| Cytoskeleton in muscle cells | KEGG | 8 / 232 | 12.9× | 1.21e-7 | 6.32e-6 ✓ sig. |
| Metabolic pathways | KEGG | 16 / 1,563 | 3.8× | 4.83e-7 | 2.08e-5 ✓ sig. |
| ECM-receptor interaction | KEGG | 5 / 89 | 21.1× | 3.43e-6 | 1.12e-4 ✓ sig. |
| Defective LARGE causes MDDGA6 and MDDGB6 | Reactome | 2 / 2 | 375× | 6.88e-6 | 1.99e-4 ✓ sig. |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | Reactome | 2 / 2 | 375× | 6.88e-6 | 1.99e-4 ✓ sig. |
| Laminin interactions | Reactome | 3 / 28 | 40.2× | 5.38e-5 | 1.07e-3 ✓ sig. |
| Arrhythmogenic right ventricular cardiomyopathy | KEGG | 4 / 86 | 17.5× | 7.56e-5 | 1.41e-3 ✓ sig. |
| Hypertrophic cardiomyopathy | KEGG | 4 / 99 | 15.2× | 1.31e-4 | 2.19e-3 ✓ sig. |
| Dilated cardiomyopathy | KEGG | 4 / 105 | 14.3× | 1.64e-4 | 2.62e-3 ✓ sig. |
| ECM proteoglycans | Reactome | 3 / 51 | 22.1× | 3.28e-4 | 4.53e-3 ✓ sig. |
| NCAM1 interactions | Reactome | 2 / 21 | 35.7× | 1.40e-3 | 1.39e-2 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| protein O-linked glycosylation via mannose | GO:0035269 | 10 / 18 | 324× | 1.96e-24 | 6.02e-21 ✓ sig. |
| protein glycosylation | GO:0006486 | 14 / 181 | 45.2× | 1.56e-20 | 2.79e-17 ✓ sig. |
| protein O-linked glycosylation | GO:0006493 | 9 / 71 | 74.0× | 2.55e-15 | 1.97e-12 ✓ sig. |
| basement membrane organization | GO:0071711 | 7 / 29 | 141× | 3.25e-14 | 2.04e-11 ✓ sig. |
| muscle organ development | GO:0007517 | 7 / 114 | 35.9× | 7.75e-10 | 1.84e-7 ✓ sig. |
| localization of cell | GO:0051674 | 3 / 6 | 292× | 9.09e-8 | 1.15e-5 ✓ sig. |
| reactive gliosis | GO:0150103 | 3 / 6 | 292× | 9.09e-8 | 1.15e-5 ✓ sig. |
| skeletal muscle fiber differentiation | GO:0098528 | 3 / 9 | 195× | 3.80e-7 | 3.82e-5 ✓ sig. |
| brain development | GO:0007420 | 6 / 244 | 14.4× | 3.18e-6 | 2.15e-4 ✓ sig. |
| glycoprotein metabolic process | GO:0009100 | 3 / 22 | 79.6× | 6.87e-6 | 3.97e-4 ✓ sig. |
| skeletal muscle tissue regeneration | GO:0043403 | 3 / 26 | 67.4× | 1.15e-5 | 5.92e-4 ✓ sig. |
| dentate gyrus development | GO:0021542 | 3 / 26 | 67.4× | 1.15e-5 | 5.92e-4 ✓ sig. |
| axon guidance | GO:0007411 | 5 / 192 | 15.2× | 1.75e-5 | 8.14e-4 ✓ sig. |
| regulation of myoblast differentiation | GO:0045661 | 2 / 6 | 195× | 4.24e-5 | 1.59e-3 ✓ sig. |
| neuromuscular process | GO:0050905 | 3 / 42 | 41.7× | 5.00e-5 | 1.81e-3 ✓ sig. |